Immunological* / therapeutic use

Glofitamab Treatment for DLBCL Shows Cost Savings Over Epcoritamab in US Healthcare

Aug 8, 2025

An economic model reveals glofitamab offers DLBCL patient cost savings versus epcoritamab, despite higher adverse event and treatment administration costs.

Recent Posts

US Govt Offers $2,000 for Water Heater Replacement Before Dec 31
Replace your old water heater with a modern, sustainable one and get a $2000 tax credit. Lower your energy bills and help the environment.
US Visa Denial May be Considered for Applicants with Chronic Health Issues
U.S. embassies may deny visas to applicants with chronic health issues, under a new directive, to prevent public cost burdens.
PA Veteran Empowers PTSD Survivors Through Fitness
Revitalizing Life with Fitness: A U.S. Army Veteran’s Inspiring Journey Erica Liermann, a U.S. Army veteran hailing from Pennsylvania, has turned her life around thanks… Read more: PA Veteran Empowers PTSD Survivors Through Fitness
Medicare Drug Coverage Selection Now More Difficult – 910News.com
Medicare Part D enrollees may face fewer plans and higher costs due to changes in legislation and market departures.
End of Year Financial Planning: Top 5 Tax Strategies for a Stronger Future
Implement financial strategies such as tax-smart moves, reassessing investments, estate planning, and business transition planning before year-end for improved tax efficiency.